• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by iRhythm Technologies Inc. (Amendment)

    2/14/23 3:22:57 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care
    Get the next $IRTC alert in real time by email
    SC 13G/A 1 13ga2_irhythm.htm


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC  20549

    SCHEDULE 13G
    (Rule 13d-102)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
    TO Section 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO
    FILED PURSUANT TO Section 240.13d-2

    Under the Securities Exchange Act of 1934
    (Amendment No. 2)


      iRhythm Technologies, Inc.
    (Name of Issuer)
     
    Common Stock, par value $0.001 per share
    (Title of Class of Securities)
     
    450056106
    (Cusip Number)
     
    December 31, 2022
    (Date of Event which Requires Filing of this Statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    S
    Rule 13d-1(b)
    ☐
    Rule 13d-1(c)
    ☐
    Rule 13d-1(d)





    13G

    CUSIP No. 450056106

    1
    NAMES OF REPORTING PERSONS
     
    Sands Capital Management, LLC
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
     
    (a) ☐      (b) X
     
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF
     
    SHARES BENEFICIALLY
    OWNED BY
     
    EACH
     
    REPORTING  PERSON WITH
    5
    SOLE VOTING POWER
     
    -0-
    6
    SHARED VOTING POWER
     
    1,763,046
    7
    SOLE DISPOSITIVE POWER
     
    -0-
    8
    SHARED DISPOSITIVE POWER
     
    2,667,428
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    2,667,428
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
    CERTAIN SHARES (See Instructions)                         
     
    ☐
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    9.1%
    12
    TYPE OF REPORTING PERSON (See Instructions)
     
    IA




    13G

    CUSIP No. 450056106

    1
    NAMES OF REPORTING PERSONS
     
    Frank M. Sands
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
     
    (a) ☐      (b) X
     
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF
     
    SHARES BENEFICIALLY
    OWNED BY
     
    EACH
     
    REPORTING  PERSON WITH
    5
    SOLE VOTING POWER
     
    -0-
    6
    SHARED VOTING POWER
     
    1,763,046
    7
    SOLE DISPOSITIVE POWER
     
    -0-
    8
    SHARED DISPOSITIVE POWER
     
    2,667,428
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    2,667,428
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
    CERTAIN SHARES (See Instructions)                         
     
    ☐
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    9.1%
    12
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN, HC




    This Amendment No. 2 to Schedule 13G amends and restates in its entirety the Schedule 13G initially filed on January 12, 2021 (together with all prior and current amendments thereto, this “Schedule 13G”).

    Item 1. Issuer

    (a) Name of Issuer:

    iRhythm Technologies, Inc. (the “Issuer”)

    (b) Address of Issuer’s Principal Executive Offices:

    699 8th Street, Suite 600
    San Francisco, California 94103

    Item 2. Identity and Background

    (a) Name of Person(s) Filing:

    This Schedule 13G is being filed jointly by Sands Capital Management, LLC (“SCM”) and Frank M. Sands (“Sands”).  Sands holds ultimate voting and investment power over securities held by SCM.

    (b) Address of Principal Business Office, or if None, Residence:

    The principal business address of each of SCM and Sands is 1000 Wilson Blvd., Suite 3000, Arlington, VA 22209.

    (c) Citizenship or Place of Organization:

    Sands Capital Management, LLC is organized under the laws of the State of Delaware.  Sands is a citizen of the United States.

    (d) Title of Class of Securities:

    Common Stock, par value $0.001 per share

    (e) CUSIP Number:

    450056106

    Item 3.
    If This Statement Is Filed Pursuant to Sections 240.13d-1(b) or 240.13d-2(b) or (c),         Check Whether the Person Filing Is an Entity Specified in (a) - (k):


    (a)
    [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);


    (b)
    [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);





    (c)
    [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);


    (d)
    [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);


    (e)
    [X] An investment adviser in accordance with Section 240.13d-1(b)(1)(ii)(E);


    (f)
    [ ] An employee benefit plan or endowment fund in accordance with
    Section 240.13d-1(b)(1)(ii)(F);


    (g)
    [X] A parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G);


    (h)
    [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);


    (i)
    [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);


    (j)
    [ ] A non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J);


    (k)
    [ ] Group, in accordance with Section 240.13d-1(b)(1)(ii)(K).

    If filing as a non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ___

    SCM is reporting hereunder as an investment adviser pursuant to (e) above.  Sands is reporting hereunder as a control person pursuant to (g) above.

    Item 4. Ownership

    See rows 5 through 11 of cover pages.

    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof each of the Reporting Persons has ceased to be a beneficial owner of more than five percent of the class of securities, check the following [  ].

    Item 6. Ownership of More than Five Percent on Behalf of Another Person

    [X] Securities reported on this Schedule 13G are held in the accounts of various clients of Sands Capital Management, LLC, which may include pension plans, endowments, foundations, mutual funds, charities, state and municipal government entities, Taft-Hartley plans, families, and individuals, among other types.  Such clients have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.  No such client’s interest in the class of securities reported herein is more than 5%.




    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company

     See Item 3.

    Item 8.
    Identification and Classification of Members of the Group

    Not applicable.

    Item 9. Notice of Dissolution of Group

    Not applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.



    SIGNATURES

    After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.


    Dated: February 14, 2023

     
    /s/ Lisa M. Grozio
     
    Sands Capital Management, LLC
     
    By: Lisa M. Grozio, Chief Compliance Officer
       
     
    /s/ Frank M. Sands
     
    Name: Frank M. Sands




    EXHIBIT INDEX


    EXHIBIT 1
    Joint Acquisition Statement Pursuant to Section 240.13d-1(k)
     




    EXHIBIT 1
    to
    SCHEDULE 13G

    JOINT ACQUISITION STATEMENT
    PURSUANT TO SECTION 240.13d-1(k)

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements.  The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him, her or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the other entities or persons, except to the extent that he, she or it knows or has reason to believe that such information is inaccurate.

    Dated:  February 14, 2023

     
    /s/ Lisa M. Grozio
     
    Sands Capital Management, LLC
     
    By: Lisa M. Grozio, Chief Compliance Officer
       
     
    /s/ Frank M. Sands
     
    Name: Frank M. Sands


    Get the next $IRTC alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $IRTC

    DatePrice TargetRatingAnalyst
    5/2/2025$130.00Equal Weight → Overweight
    Wells Fargo
    12/3/2024$86.00Equal Weight
    Wells Fargo
    10/4/2024$78.00Neutral
    Goldman
    6/20/2024$115.00Peer Perform → Outperform
    Wolfe Research
    12/11/2023$110.00Neutral → Buy
    Citigroup
    7/19/2023$130.00Outperform
    Robert W. Baird
    2/7/2023$150.00Overweight
    Wells Fargo
    11/7/2022Underperform → Peer Perform
    Wolfe Research
    More analyst ratings

    $IRTC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Talwalkar Abhijit Y bought $500,866 worth of shares (6,664 units at $75.16), increasing direct ownership by 54% to 18,941 units (SEC Form 4)

      4 - iRhythm Technologies, Inc. (0001388658) (Issuer)

      11/5/24 11:59:44 AM ET
      $IRTC
      Medical/Dental Instruments
      Health Care
    • Chief Commercial Officer Patterson Chad bought $20,994 worth of shares (280 units at $74.98) and sold $224,876 worth of shares (3,012 units at $74.66), decreasing direct ownership by 7% to 37,133 units (SEC Form 4)

      4 - iRhythm Technologies, Inc. (0001388658) (Issuer)

      8/5/24 5:35:18 PM ET
      $IRTC
      Medical/Dental Instruments
      Health Care
    • Blackford Quentin S. bought $997,644 worth of shares (9,755 units at $102.27), increasing direct ownership by 8% to 128,510 units (SEC Form 4) (Amendment)

      4/A - iRhythm Technologies, Inc. (0001388658) (Issuer)

      12/6/23 7:08:38 PM ET
      $IRTC
      Medical/Dental Instruments
      Health Care

    $IRTC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • iRhythm upgraded by Wells Fargo with a new price target

      Wells Fargo upgraded iRhythm from Equal Weight to Overweight and set a new price target of $130.00

      5/2/25 8:03:46 AM ET
      $IRTC
      Medical/Dental Instruments
      Health Care
    • Wells Fargo resumed coverage on iRhythm with a new price target

      Wells Fargo resumed coverage of iRhythm with a rating of Equal Weight and set a new price target of $86.00

      12/3/24 7:33:58 AM ET
      $IRTC
      Medical/Dental Instruments
      Health Care
    • Goldman initiated coverage on iRhythm with a new price target

      Goldman initiated coverage of iRhythm with a rating of Neutral and set a new price target of $78.00

      10/4/24 7:40:56 AM ET
      $IRTC
      Medical/Dental Instruments
      Health Care

    $IRTC
    SEC Filings

    See more
    • iRhythm Technologies Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - iRhythm Technologies, Inc. (0001388658) (Filer)

      7/7/25 5:16:57 PM ET
      $IRTC
      Medical/Dental Instruments
      Health Care
    • SEC Form 144 filed by iRhythm Technologies Inc.

      144 - iRhythm Technologies, Inc. (0001388658) (Subject)

      6/10/25 6:06:16 PM ET
      $IRTC
      Medical/Dental Instruments
      Health Care
    • iRhythm Technologies Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - iRhythm Technologies, Inc. (0001388658) (Filer)

      5/30/25 4:01:53 PM ET
      $IRTC
      Medical/Dental Instruments
      Health Care

    $IRTC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mcginnis Karen K was granted 2,035 shares (SEC Form 4)

      4 - iRhythm Technologies, Inc. (0001388658) (Issuer)

      7/8/25 4:23:16 PM ET
      $IRTC
      Medical/Dental Instruments
      Health Care
    • Director Oboyle Kevin C was granted 2,035 shares (SEC Form 4)

      4 - iRhythm Technologies, Inc. (0001388658) (Issuer)

      7/8/25 4:22:49 PM ET
      $IRTC
      Medical/Dental Instruments
      Health Care
    • SEC Form 3 filed by new insider Mcginnis Karen K

      3 - iRhythm Technologies, Inc. (0001388658) (Issuer)

      7/8/25 4:21:47 PM ET
      $IRTC
      Medical/Dental Instruments
      Health Care

    $IRTC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Artificial Intelligence Revolutionizing Early Detection of Diabetic Retinopathy Creating a Multi-Billion Dollar Revenue Opportunity

      MarketNewsUpdates News Commentary NEW YORK, July 15, 2025 /PRNewswire/ -- Artificial Intelligence (AI) algorithms are revolutionizing the way retina images are analyzed for detecting conditions such as age-related macular degeneration (AMD) and diabetic retinopathy. These advanced algorithms often achieve diagnostic accuracies that equal or surpass human experts, especially in complex cases. This capability not only enhances diagnostic precision but also supports clinicians in delivering more effective treatment strategies.  AI systems that analyze retina images can spot early signs of diseases like age-related macular degeneration (AMD) and diabetic retinopathy. These conditions often devel

      7/15/25 8:45:00 AM ET
      $ABT
      $DXCM
      $IRTC
      $TNDM
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
    • iRhythm Technologies Announces Board Member Retirements and New Director Appointments

      SAN FRANCISCO, July 07, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) , a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced the retirement of two long-serving board members, Mark Rubash and Ralph Snyderman, M.D., effective July 7, 2025. Concurrently, Karen McGinnis and Kevin O'Boyle have accepted appointments to the board of directors. Mark Rubash has served on the board since 2016, prior to the company's initial public offering, bringing decades of experience in finance, accounting, and strategy at high-growth technology companies. Ralph Snyderman, M.D., who joined the board in 2017, br

      7/7/25 8:30:00 AM ET
      $ABSI
      $ATEC
      $ILMN
      $IRTC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
      Medical/Dental Instruments
      Medical Specialities
    • New Data Presented at ADA 2025 Highlights Burden and Risk Associations of Cardiac Arrhythmias in Patients with Type 2 Diabetes and Chronic Kidney Disease

      SAN FRANCISCO, June 23, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) announced the results from two large-scale real-world studies presented at the American Diabetes Association's 85th Scientific Sessions (ADA 2025). The analyses reveal that cardiac arrhythmias are common and often occur early in people with type 2 diabetes (T2D)—especially those who also have chronic kidney disease (CKD). These findings suggest a critical opportunity to enhance early detection strategies in at-risk cardiometabolic populations. The studies examined longitudinal claims data from over 30 million U.S. adults, providing new insights into how arrhythmias—often asymptomatic—cluster around

      6/23/25 8:30:00 AM ET
      $IRTC
      Medical/Dental Instruments
      Health Care

    $IRTC
    Leadership Updates

    Live Leadership Updates

    See more
    • iRhythm collaborates with Epic to streamline access to Zio® service and drive more seamless connectivity between clinicians and patients

      iRhythm is the first medical device company to join the Epic community, using Aura to drive efficiencies through EHR integrationThe collaboration will expand access to Zio service across the continuum of patient care—from cardiology to primary care to emergency departments and beyond1 SAN FRANCISCO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital healthcare company focused on creating trusted solutions that detect, predict, and prevent disease, today announced it will use Epic's Aura platform to streamline access to iRhythm's Zio long-term continuous monitoring and ambulatory mobile cardiac telemetry services ("Zio services") through improved

      2/29/24 4:30:00 PM ET
      $IRTC
      Medical/Dental Instruments
      Health Care
    • Derrick Sung Joins Aerin Medical as Chief Financial Officer

      A seasoned leader, Sung brings deep finance, capital markets, and strategy experience across the medical device industry Aerin Medical Inc., a company dedicated to providing Ear, Nose and Throat (ENT) physicians with non-invasive solutions for the treatment of chronic nasal conditions, announced today that Derrick Sung has been appointed chief financial officer of the company. Sung brings over 25 years of finance, capital markets, and strategy experience across diverse roles within the medical device industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231120576987/en/Derrick Sung has been appointed chief financial officer

      11/20/23 9:00:00 AM ET
      $IRTC
      $LUNG
      Medical/Dental Instruments
      Health Care
    • iRhythm Technologies Further Strengthens its Board of Directors with Two New Independent Director Appointments

      SAN FRANCISCO, June 06, 2023 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced the appointment of Mojdeh Poul and Brian Yoor as directors to its Board effective June 1, 2023. "On behalf of the entire iRhythm team, I am thrilled to welcome Mojdeh and Brian to our Board of Directors," said Quentin Blackford, iRhythm's President and CEO. "Both bring extensive operational experience, strong financial acumen, and public company leadership across the global healthcare and medical technology sectors. We believe their proven track record of delivering

      6/6/23 9:00:39 AM ET
      $IRTC
      Medical/Dental Instruments
      Health Care

    $IRTC
    Financials

    Live finance-specific insights

    See more
    • iRhythm Technologies Announces First Quarter 2025 Financial Results

      SAN FRANCISCO, May 01, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended March 31, 2025. First Quarter 2025 Financial Highlights Revenue of $158.7 million, a 20.3% increase compared to first quarter 2024Gross margin of 68.8%, a 250-basis point increase compared to first quarter 2024Unrestricted cash, cash equivalents, and marketable securities of $520.6 million as of March 31, 2025Increased fiscal year 2025 guidance for revenue and adjusted EBITDA margin Recent Operational Highlights Strong qu

      5/1/25 4:05:00 PM ET
      $IRTC
      Medical/Dental Instruments
      Health Care
    • iRhythm Technologies to Report First Quarter 2025 Financial Results on May 1, 2025

      SAN FRANCISCO, April 17, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the first quarter 2025 after the close of trading on Thursday, May 1, 2025. The company's management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET. Interested parties may access a live and archived webcast of the conference call on the "Quarterly Results" section of the company's investor website at investors.irhythmtech.com. About iRhythm Technologies, Inc. iRhythm is a leading di

      4/17/25 4:30:00 PM ET
      $IRTC
      Medical/Dental Instruments
      Health Care
    • iRhythm Technologies Announces Fourth Quarter and Full Year 2024 Financial Results

      SAN FRANCISCO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months and full year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights Revenue of $164.3 million, a 24.0% increase compared to fourth quarter 2023Gross margin of 70.0%, a 410-basis point increase compared to fourth quarter 2023Net loss of $1.3 million, a $37.4 million improvement compared to fourth quarter 2023Adjusted EBITDA of $19.3 million, a $16.9 million improvement compared to fourth quarter 2023Cash, cash equ

      2/20/25 4:05:00 PM ET
      $IRTC
      Medical/Dental Instruments
      Health Care

    $IRTC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by iRhythm Technologies Inc.

      SC 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)

      11/12/24 12:54:21 PM ET
      $IRTC
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by iRhythm Technologies Inc.

      SC 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)

      11/12/24 9:52:49 AM ET
      $IRTC
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by iRhythm Technologies Inc.

      SC 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)

      11/7/24 4:05:49 PM ET
      $IRTC
      Medical/Dental Instruments
      Health Care